Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 10/20 | 0.58 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 2/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | NSD2 | O96028 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | GALK1 | P51570 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HKDC1 | Q2TB90 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.47 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21917753 | 0.88 | NOTUM (0.50) | NOTUMAKR1C3USP2LMNAMAPT | |
| SCHEMBL20841042 | 0.87 | MAPT (0.48) | NOTUMUSP2LMNAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL28304540 | 0.84 | RORC (0.52) | NOTUMLMNAALDH1A1MAPTTHRB | |
| SCHEMBL14924001 | 0.83 | RORC (0.51) | NOTUMLMNAALDH1A1MAPTTHRB | |
| SCHEMBL20884550 | 0.82 | HRH3 (0.44) | NOTUMUSP2LMNAALDH1A1MAPT | |
| SCHEMBL6506958 | 0.82 | NOTUM (0.85) | NOTUMUSP2MAPTTHRBAPAF1 | |
| SCHEMBL3570102 | 0.81 | NOTUM (0.57) | NOTUMAKR1C3USP2LMNAALDH1A1 | |
| SCHEMBL2073478 | 0.81 | NOTUM (0.81) | NOTUMAKR1C3LMNAALDH1A1MAPT | |
| SCHEMBL2070467 | 0.81 | NOTUM (0.57) | NOTUMAKR1C3USP2LMNAMAPT | |
| Hydrochloric Acid SCHEMBL3571310 | 0.80 | NOTUM (0.56) | NOTUMAKR1C3USP2LMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | EMORY UNIVERSITY | 2022-01-06 | — | — | US | disclosed |
| US-11077120-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2021-08-03 | — | — | US | disclosed |
| US-20200085837-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | UNIV EMORY (US) | 2020-03-19 | — | — | US | disclosed |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | EMORY UNIVERSITY (US) | 2020-02-25 | — | — | US | disclosed |
| CN-110016020-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-07-16 | — | — | CN | disclosed |
| CN-109384778-A | Use of a compound or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease, health condition or disorder | 铁木医药有限公司 | 2019-02-26 | — | — | CN | disclosed |
| CN-109369635-A | Compound or pharmaceutically acceptable salt thereof, application and pharmaceutical composition thereof | 铁木医药有限公司 | 2019-02-22 | — | — | CN | disclosed |
| CN-108912111-A | compounds and pharmaceutical compositions | 铁木医药有限公司 | 2018-11-30 | — | — | CN | disclosed |
| CN-105408328-B | sGC stimulators | 铁木医药有限公司 | 2018-11-16 | — | — | CN | disclosed |
| CN-107406422-A | Pyrazole derivatives as sGC stimulants | 铁木医药有限公司 | 2017-11-28 | — | — | CN | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-RE46511-E1 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2017-08-15 | — | — | US | disclosed |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-02-16 | — | — | US | disclosed |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2016-08-11 | — | — | US | disclosed |
| US-9345719-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD. (KR) | 2016-05-24 | — | — | US | disclosed |
| US-8957065-B2 | Fused pyrimidine derivatives for inhibition of tyrosine kinase activity | HANMI SCIENCE CO., LTD (KR) | 2015-02-17 | — | — | US | disclosed |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD (KR) | 2015-02-12 | — | — | US | disclosed |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | HANMI SCIENCE CO., LTD. (KR) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220000883-A1 | PROSTAGLANDIN RECEPTOR EP2 ANTAGONISTS, DERIVATIVES, COMPOSITIONS, AND USES RELATED THERETO | PTGER2, PTGES2, PTGER1 | NOTUM 1460/4885AKR1C3 954/4885USP2 1277/4885 |
| US-11077120-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGES | NOTUM 1723/4885AKR1C3 929/4885USP2 1387/4885 |
| US-20160229868-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, LTK, FYN | NOTUM 3672/4885AKR1C3 4354/4885USP2 2132/4885 |
| US-10568889-B2 | Prostaglandin receptor EP2 antagonists, derivatives, compositions, and uses related thereto | PTGER2, PTGES2, PTGER1 | NOTUM 1460/4885AKR1C3 954/4885USP2 1277/4885 |
| US-20200085837-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | NOTUM 1460/4885AKR1C3 954/4885USP2 1277/4885 |
| US-20150045324-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | NOTUM 3498/4885AKR1C3 4210/4885USP2 2277/4885 |
| US-20170042905-A1 | Prostaglandin Receptor EP2 Antagonists, Derivatives, Compositions, and Uses Related Thereto | PTGER2, PTGES2, PTGER1 | NOTUM 1460/4885AKR1C3 954/4885USP2 1277/4885 |
| US-20130116213-A1 | NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY | LCK, FYN, TYK2 | NOTUM 3498/4885AKR1C3 4210/4885USP2 2277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.